Replies to post #8011 on Zivo Bioscience Inc (ZIVO)

[weazelboy]

Ya, I only managed to get about 2k shares in the 2.20s (best execution is 2.245). Most of the rest is in 2.40s.

I also was hesitant to load full...as I wanted to be prepared for a potential death drop as well. lol

Those offers were clearly being used in an attempt to push down the stock/clean it up. ie- trying to force out weak hands to eliminate gunshy sellers. This makes run attempt easier as it's cleaner. They're showing all the signs of preparation to do something with the stock...but, will they do it? Similar action last year...and nothing came of it.

[Amigo Mike]

LOL,

Like I told you last month ... it is TRADING ....
and ZIVO is UNINVESTABLE until it's not. <=== That is something Payne needs to change YESTERDAY.

And assuming nothing happened negative, I'd be standing at the window with a fist full of $$$$ if this stock were to even sniff $1.75.

ZIVO put the timeline out there last year. September 23rd was the date. It's It's time to hear from them on the major animal health company testing. IMO, this is material information as bad news is detrimental to the company .... good news yields the potential for a license. So if they have it ... IMO .... I think it needs to be released ..... if they don't .... then they need to be ready to release once received and confirmed.

In no way should investors be left waiting .... on whatever the result is.

To execute on our refocused biotech strategy, we recently engaged with a leading global animal health company. Our in-depth discussions with this company have led to an interest in our product candidate as a complement to their existing poultry feed additive product portfolio. ZIVO has signed a material transfer and evaluation agreement to allow our potential partner to run validation testing on our lead product candidate. Discussions remain ongoing and there can be no assurance they will result in a definitive agreement, yet we expect to have more clarity in the first quarter of 2023 following the completion of their internal and third-party validation studies.

Our potential partner has begun a four-month comprehensive validation study of our product candidate, including a 42-day coccidiosis trial in broiler chickens. Results from the validation study are expected in the first quarter of 2023. We remain confident this validation study will again confirm the desired efficacy profile given ZIVO’s numerous prior successful studies. Pending positive results from the ongoing trial, our goal will be to secure a development and license agreement in the first half of next year.

January 23rd is a full 4 months. Surely the 42 day study has already been completed.
Results are expect NOW.

Amigo Mike